Retrospective Study Of The Influence Of Age At Start Of Growth Hormone Treatment On Height Gain In Children Born Small for Gestational Age

Retrospective Study Of The Influence Of Age At Start Of Growth Hormone (Gh) Treatment On Height Gain In Children Born Small for Gestational Age (SGA)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01897753

Acronym

GH-RAST

Enrollment

264

Registered

2013-07-12

Start date

2012-03-31

Completion date

2013-09-30

Last updated

2014-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small For Gestational Age (SGA)

Keywords

SGA, Growth hormone

Brief summary

The purpose of this protocol is to retrospectively study the influence of age at start of growth hormone (GH) treatment on height gain in children born small for gestational age (SGA).

Interventions

DRUGgrowth hormone

36 months

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

4 Years to No maximum

Healthy volunteers

Inclusion criteria

* SGA children. * Treated with GH at least 36 months.

Exclusion criteria

* Patients treated with GH for other indications (not SGA).

Design outcomes

Primary

Measure	Time frame	Description
height SDS	36 months	height SDS of SGA children after 36 months of treatment

Secondary

Measure	Time frame	Description
height increase	36 months	—
Change from Baseline in Lipid Parameters at Month X	36 months	Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026